Posts Tagged ‘GLP-1 agonists’

Right now, the promise of GLP-1 medicines for obesity, though revolutionary, is serving only to widen the economic rift in health. People with extraordinary wealth or generous health insurance plans receive the health benefits that flow from treating obesity effectively – which include a longer life, fewer strokes, and fewer heart attacks. Others are consigned […]

We are hearing a cacophony lately – lots of noise about food noise. Part of what we hear is a celebration. Some people are finding blessed relief from it when they take advanced medicines for obesity like semaglutide or tirzepatide. Others see a threat in the relief that those people are finding. They deny that […]

In the New Yorker, Dhruv Khullar calls 2023 “the year of Ozempic.” Then in Vox, Constance Grady puts it right up there with Barbie, calling this “the year of Ozempic bodies and Barbie Botox.” The New York Times puts it at the very top of five health lessons we learned in 2023. Most notably, Science […]

The approach of the big holiday of Christmas often conjures thoughts about sharing meals and festive food. Many tables are overflowing with excess and with that excess comes a certain amount of angst about holiday food, health, and personal happiness. This year, we have a new twist on how to cope. Popular media is serving […]

No two ways about it. This has been a big year of milestones in obesity and health. We and many others are still processing what we have witnessed in these past 12 months. But one way to gain perspective is to look at 2023 stats for the posts on ConscienHealth that you, a wise group […]

For some time now, scientists have noted that GLP-1 agonists have effects on more than just blood sugar and body weight. They seem to have an effect on systemic inflammation. For more than a decade, researchers have been exploring their anti-inflammatory effects. But a key question has remained: exactly how do GLP-1 agonists help with […]

“Are you sure you want an Ozempic pill?” In the Atlantic, Yasmin Tayag poses this question. Back in June people were bubbling with enthusiasm at the prospect of an oral small molecule – orforglipron – that might work as well as injectable semaglutide. But Tayag offers caution that we share. One size, one approach, for […]

It’s long been overdue. For as long as we can remember, one presumption has been dominant. The real cure for obesity is (supposed to be) a change in lifestyle. It is the “foundation of obesity treatment” says just about everyone, even today. But the sand underneath that foundation is shifting. So the time has come […]

Truly, access to care for obesity is a tough slog. Not that it’s easy for any health condition. Obesity really is a special case, where medical care that can improve a person’s health often lies just out of reach. Bias about obesity is part of the problem. Fear of mounting medical costs is another. But […]

We have grown tired of the mindless repetition of a $1,350 monthly list price for Wegovy in endless news reports about the great expense of this very important new drug for obesity. Not because the drug isn’t expensive. But because that list price is not an accurate representation of what the drug really costs. So […]